Exelixis Puts 45-Day Limit on Requests to Reclassify Past Sales as 340B Purchases

Exelixis
Exelixis says starting May 15 it will honor 340B covered entities' requests to replenish/reclassify prior purchases that were not made at the 340B ceiling price only within 45 days of the date that the drug was dispensed.

Starting May 15, biopharmaceutical manufacturer Exelixis will require 340B covered entities that want past drug purchases that were not made at the 340B ceiling price to be reclassified as 340B sales to do so within 45 days of the date

Read More »

340B-Related Amendment Might Be Offered to PBM Reform Bill That Senate Panel Is Trying to Mark Up Today

Mike Braun
Sen. Mike Braun (R-Ind.) is expected offer an amendment in committee today to PBM reform legislation to require 340B hospitals to be more transparent about how they use 340B program savings.

A U.S. Senate committee is attempting to mark up bipartisan legislation today to reform the pharmacy benefit management industry. The draft bill itself does not address the 340B program. Republican Sen. Mike Braun (Ind.), however, has filed an amendment for

Read More »

Judge Denies Health Center’s Request for More Government Files in 340B Patient Definition Case

Genesis
Genesis Health Care successfully challenged HRSA's 340B patient definition in the U.S. District Court for the District of South Carolina.

A federal district judge last week declined to make federal health officials give a South Carolina health center any more documents linked to the center’s brief expulsion from and subsequent reinstatement to the 340B program in 2018.

U.S. Chief District

Read More »

340B Stifles Biosimilar Uptake, Study in Health Affairs Says

Health Affairs
New research in Health Affairs says 340B hospitals are less likely than others to use biosimilar drugs due to financial incentives to use more expensive reference drugs instead.

Research published online yesterday in the journal Health Affairs suggests that 340B hospitals are less likely than others to use biosimilar drugs, “possibly as a result of financial incentives making reference drugs more profitable than biosimilar medications.”

Groups that represent

Read More »

340B COVID-19 Flexibilities Will End May 11 as Public Health Emergency Expires

HRSA
340B program flexibilities allowed under the COVID-19 public health emergency will expire May 11, HRSA said Monday.

Certain flexibilities to the 340B program allowed under the COVID-19 public health emergency will expire May 11 alongside the PHE, the U.S. Health Resources and Services Administration announced Monday.

The update, which HRSA posted prominently on the Office of Pharmacy

Read More »

Astellas Notifies 340B Entities for Second Time in 2023 About a Change in Drug’s NDC

Cresemba
Astellas says for 340B replenishment, the new and old NDCs of Cresemba’s 372mg intravenous formulation are interchangable.

Drug maker Astellas will let 340B covered entities count accumulations of an injectable form of its antifungal drug Cresemba under its old National Drug Code toward replenishment of equal quantities under the product’s corresponding new NDC, provided the entities use

Read More »

News Alert

Bayer Announces Tougher Limits on 340B Pricing for Hospitals

Bayer
Bayer today significantly tightened its limits on 340B pricing when hospitals contract with pharmacies to dispense drugs to patients.

Drug manufacturer Bayer this morning significantly tightened its limits on 340B pricing when hospital covered entities contract with pharmacies to dispense drugs to patients. Grantee entities remain exempt from Bayer’s restrictions.

Covered entities reported receiving letters from Bayer about

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report